Monique Minnema

 

SPECIALISMS:

  • Multiple Myeloma
  • Morbus Waldenstrom
  • AL amyloidosis
  • Phase I/II clinical studies
  • Immunotherapy

PubMed

 

Biography

Dr Monique Minnema was trained as internist and hematologist at the Academic Medical Center, Amsterdam and the University Medical Center, Utrecht. She started working as a hematologist in 2005 at the department of hematology, UMC Utrecht and specialized in the diagnosis and treatment of B cell malignancies, especially plasma cell dyscrasias, like Multiple Myeloma, AL amyloidosis, and Morbus Waldenström. She is the medical head of the hematology research team which supervises more than 20 clinical studies. Her main focus of clinical research is the development of novel therapies (both cellular and drug) developments for plasma cell dyscrasias and lymphoma. She is a member of the HOVON working parties for multiple myeloma, lymphoma and the Lunenburg Lymphoma consortium (LLPC) for phase I/II studies. Dr Minnema is the principal investigator of the HOVON 104 trial for patients with AL amyloidosis first line treatment, the clinical studies with the monoclonal antibody Daratumumab in relapsed Multiple Myeloma and the checkpoint inhibitor Nivolumab in relapsed Lymphoma. Translational research focuses on the anti-apoptotic pathway in Multiple Myeloma and bone remodeling after successful anti myeloma treatment. She is a member of the organizing committee of the Waldenström workshop in Amsterdam in 2016.

Research Projects

  • 3D bone marrow model for multiple myeloma
  • Innate immune system therapy for multiple myeloma treatment
  • Liquid biopsies in rare lymphoma cancers
  • Anti MAG IgM neuropathy and MYD88 prevalence
  • HOVON 104;  A multicenter, prospective study of bortezomib and dexamethasone as induction treatment followed by high dose melphalan and autologous stem cell transplantation in patients with de novo amyloid light chain (AL) amyloidosis

Current External Activities

  • ASH member
  • EBMT member
  • EHA Member
  • HOVON Multiple Myeloma working party
  • HOVON Lymphoma working party
  • HOVON LLPC working party
  • European Myeloma Network
  • European Waldenström Network
  • Medical advisory board patient organization Hematon
  • Medical advisory board patient organization Amyloidosis
  • Medical advisory board patients organization EWN
  • Chair international task force Bing Neel

Scientific Publications

5 most recent key publications:

  • Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19 

  • Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood, 2016 Aug 16.
     
  • Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA. Treatment recommendations for Waldenström macroglobulinemia from the Eighth International Workshop on WM. Blood. 2016 Jul 18
     
  • de Haart SJ, Willems SM, Mutis T, Koudijs MJ, van Blokland MT, Lokhorst HM, de Weger RA, Minnema MC. Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses. Blood Cancer J. 2016 May 20;6:e426
     
  • de Haart SJ, Holthof L, Noort WA, Minnema MC, Emmelot ME, Aarts-Riemens T, Doshi P, Sasser K, Yuan H, de Bruijn J, Martens ACM, van de Donk NWCJ, Lokhorst HM, Groen RWJ, Mutis T. Sepantronium Bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. Haematologica 2016;101(8):e339-42

GRANTS

  • AICR 2013; Unraveling and Modulation of microenvironment-mediated immune resistance in Multiple Myeloma

Clinical trials

  • HOVON 104; A multicenter, phase II study of bortezomib and dexamethasone as induction treatment followed by high dose melphalan (HDM) and autologous stem cell transplantation (SCT) in patients with de novo amyloid light chain (AL) amyloidosis
  • Checkmate 205; Non-Comparative, Two-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT)
  • VITAL; A phase 3, randomized, multicenter, double-blind, placebo-controlled, 2-Arm, efficacy and safety study of NEOD001 plus standard of care vs. placebo plus standard of care in subjects with Light Chain (AL) Amyloidosis
  • HOVON 124 WM/ECWM-R2 study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström’s macroglobulinemia
  • DARA-ATRA; A phase 1 and phase 2 study of Daratumumab in combination with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma

Associated Team Members

  • Reinier Raymakers (hematologist)

  • Margot Jak (hematologist)

  • Clinical study team members;
    Anna van Muijden, Klaartje Nijssen, Linda van Dommelen (trial managers), Els Spelt-Buchner, secretaresse, Mirjam Kruizinga-Hartgers, verpleegkundige